UK: PEPTIDE IN TAKEOVER DISCUSSIONS?
Article Abstract:
Peptide Therapeutics, the UK biotechnology company, is thought to be in takeover discussions, although no formal bid has been made. The most likely potential purchasers are Cantab Pharmaceuticals, Oxford Biomedica and Powderject with a Sutherlands Ltd analyst citing Cantab as the most likely prospect. A rise in Peptide's share price on 05 January 2000 on rumours of a possible takeover contrasts with a heavy fall in the share price in the latter part of 1999.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
UK: OXFORD BIOMEDICA TO MAKE FULL LISTING
Article Abstract:
Oxford Biomedica
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
The arranged marriage
Article Abstract:
It is widely believed that the 48 billion pounds sterling all-share merger of UK pharmaceutical concern Zeneca with Astra, its Swedish competitor, will resolve problems at both companies. The deal has already been approved by Zeneca shareholders, and will be ratified by Astra investors in Mar 1999. The merged operation will have sales of 10 billion pounds sterling a year and more than 40,000 employees, making it the third-largest pure pharmaceutical concern in the world. It will have a research and development budget of around $1.9 billion, making it a powerful force in drug development.
Comment:
Has merged with Astra AB
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1999
User Contributions:
Comment about this article or add new information about this topic: